Moderna, Inc. (NASDAQ:MRNA) Given Consensus Recommendation of “Hold” by Brokerages

Moderna, Inc. (NASDAQ:MRNA) has been given an average recommendation of “Hold” by the twenty-four ratings firms that are currently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $59.00.

MRNA has been the topic of a number of analyst reports. Bank of America decreased their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 11th. Morgan Stanley decreased their price target on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. JPMorgan Chase & Co. cut their price objective on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Friday, March 21st. Barclays lowered shares of Moderna from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a report on Tuesday, February 18th.

Hedge Funds Weigh In On Moderna

Hedge funds have recently made changes to their positions in the business. Allworth Financial LP increased its holdings in Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after purchasing an additional 281 shares in the last quarter. Howard Capital Management Inc. grew its stake in shares of Moderna by 3.1% in the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock valued at $416,000 after buying an additional 297 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after buying an additional 317 shares in the last quarter. Empowered Funds LLC lifted its position in Moderna by 6.6% during the 3rd quarter. Empowered Funds LLC now owns 5,199 shares of the company’s stock worth $347,000 after acquiring an additional 322 shares in the last quarter. Finally, Itau Unibanco Holding S.A. boosted its holdings in Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock worth $42,000 after acquiring an additional 343 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

MRNA stock opened at $32.12 on Friday. The stock’s 50 day moving average price is $34.78 and its 200 day moving average price is $44.93. The firm has a market cap of $12.42 billion, a P/E ratio of -3.46 and a beta of 1.86. Moderna has a 1 year low of $29.25 and a 1 year high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.